Silo Wellness Announces Prepayment for up to 5,000 10mg Psilocybin Units for Oregon Licensed Silo Affiliates
Silo Wellness Announces Prepayment for up to 5,000 10mg Psilocybin Units for Oregon Licensed Silo Affiliates
Springfield, Oregon--(Newsfile Corp. - April 24, 2023) - Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo" or "the Company") is pleased to announce that it will be prepaying USD$50,000 in stock for Oregon psilocybin mushrooms under its Right of First Refusal agreement with Satya, Inc announced on March 24, 2023. The prepayment is not for a mushroom purchase but will be a credit to be used by the Company's future OHA-licensed affiliates. This prepayment secures the right to supply psilocybin mushrooms containing up to 5,000 doses of 10mg of psilocybin analyte. The prepayment is estimated to be enough to supply 1,000 doses of approximately five grams of dried mushrooms, depending on lab-tested potency.
俄勒岡州斯普林菲爾德--(Newsfile Corp.——2023年4月24日)——Silo Wellness Inc.(CSE:SILO)(OTCQB:SILFF)(FSE:3K7A)(“Silo” 或 “公司”)欣然宣佈,根據與薩蒂亞公司簽訂的優先拒絕權協議,它將爲俄勒岡州的psilocybin蘑菇預付5萬美元的股票,2023。預付款不是用於購買蘑菇,而是公司未來獲得OHA許可的關聯公司使用的抵免額。這筆預付款確保了供應含有多達5,000劑10mg的裸蓋菇素分析物的psilocybin蘑菇的權利。據估計,這筆預付款足以供應1,000劑約五克的幹蘑菇,具體取決於實驗室測試的效力。
In compliance with the agreement terms, Silo Wellness will issue 3,422,375 shares of its common stock to settle the USD$50,000 account payable debt in an arm's length transaction subject to the statutory four-month hold. The number of shares is determined based on CAD$0.0198 per share, the 20-day volume-weighted average price (VWAP) as of Friday, April 21, 2023. Pursuant to CSE Policy 6.2(5) (adopted April 3, 2023), the Company intends to close on the share issuance no sooner than five days. The price protection expires June 5, 2023. In accordance with the previously announced debt restructuring plan, the Company intends to issue shares to settle additional accounts payable and other debt.
根據協議條款,Silo Wellness將發行3,422,375股普通股,以在正常交易中結清5萬美元的應付賬款債務,但須遵守法定持有期爲四個月。股票數量根據每股0.0198加元確定,即截至2023年4月21日星期五的20天成交量加權平均價格(VWAP)。根據CSE政策6.2(5)(2023年4月3日通過),公司打算在五天內完成股票發行。價格保護將於2023年6月5日到期。根據先前宣佈的債務重組計劃,公司打算髮行股票以結清額外的應付賬款和其他債務。
Mike Arnold, Silo CEO, stated: "It is our goal to ensure an orderly early market with the medicine distributed in a fair and equitable manner. We invite current and planned Oregon psilocybin service center licensees and facilitators to contact us to discuss becoming affiliates and ensuring a guaranteed supply of psilocybin mushrooms for their clients."
Silo首席執行官邁克·阿諾德表示:“我們的目標是確保藥品以公平和公平的方式分銷有序的早期市場。我們邀請俄勒岡州現任和計劃中的psilocybin服務中心許可證持有人和協調人聯繫我們,討論如何成爲分支機構並確保爲其客戶保證裸蓋菇的供應。”
About Silo Wellness
關於筒倉健康
Silo Wellness's mission is to provide psychedelics to those suffering as quickly and inexpensively as possible. Silo is currently Oregon's only publicly traded company actively providing psychedelics to clients. The Company was founded in 2018 by an Oregon trial lawyer in anticipation of Oregon legalizing psilocybin on January 1, 2023, and currently offers Jamaica psilocybin retreats at an all-inclusive seafront resort. The Company has a right of first refusal on all psilocybin mushrooms with Oregon first-mover cultivator Satya, Inc., and announced in January its intended Portland-area rural psilocybin service center with overnight dorm room accommodations (if land use permits are granted).
Silo Wellness 的使命是儘可能快且廉價地爲受苦的人提供迷幻藥。Silo是俄勒岡州目前唯一一家積極向客戶提供迷幻藥的上市公司。該公司由俄勒岡州的一位出庭律師於2018年創立,預計俄勒岡州將於2023年1月1日將psilocybin合法化,目前在全包式海濱度假勝地提供牙買加psilocybin度假勝地。該公司擁有俄勒岡州先發培育商Satya, Inc. 對所有psilocybin蘑菇擁有優先拒絕權,並在1月份宣佈其計劃在波特蘭地區農村psilocybin服務中心提供過夜宿舍住宿(如果獲得土地使用許可)。
Contact:
Mike Arnold, CEO
541-900-5871
IR at silo wellness dot com
聯繫人:
邁克·阿諾德,首席執行官
541-900-5871
IR at silo wellnessds
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. SEE PRIOR PRESS RELEASES AND ANNUAL FILINGS FOR CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS. SEE THE MOST RECENT MD&A ON SEDAR FOR RISK FACTORS.
加拿大證券交易所及其監管服務提供商均不對本新聞稿的充分性或準確性承擔責任。有關前瞻性陳述的警示說明,請參閱先前的新聞稿和年度文件。查看最新的 MD&A 塞達爾 用於風險因素。
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問